✦ LIBER ✦

Testosterone potentiated 32P therapy in prostatic carcinoma

✍ Scribed by Robert M. Donati; Harry Ellis; Neil I. Gallagher

Publisher: John Wiley and Sons
Year: 1966
Tongue: English
Weight: 280 KB
Volume: 19
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(196608)19:8<1088::aid-cncr2820190806>3.0.co;2-o

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Buserelin as primary therapy in advanced

Buserelin as primary therapy in advanced prostatic carcinoma

✍ Cary A. Presant; Mark S. Soloway; Sol S. Klioze; John W. Kosola; Alun L. Yakabow 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 369 KB 👁 2 views

Pharmacodynamic model of testosterone su

Pharmacodynamic model of testosterone suppression after intramuscular depot estrogen therapy in prostate cancer

✍ C.-J. Johansson; P.O. Gunnarsson 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 201 KB 👁 1 views

## BACKGROUND. A long-acting parenteral depot estrogen, polyestradiol phosphate (PEP), which has been in clinical use for several years in combination therapy, has been reevaluated pharmacokinetically and clinically as a single treatment. The present report describes a model predicting the effect

Adjuvant 32P in the treatment of ovarian

Adjuvant 32P in the treatment of ovarian carcinoma

✍ Kellie S. Condra; William M. Mendenhall; Linda S. Morgan; Robert B. Marcus Jr. 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 1 views

The purpose of this study was to evaluate the efficacy of adjuvant 32 P for patients with high-risk, early-stage ovarian carcinoma. Twenty-five patients underwent apparent complete resection followed by 32 P (15 mCi) at the University of Florida between 1976 and 1993. Minimum and median follow-up ti

Mitoxantrone in patients with prostate s

Mitoxantrone in patients with prostate specific antigen progression after local therapy for prostate carcinoma

✍ Robert S. DiPaola; Eric S. Chenven; Weichung J. Shih; Yong Lin; Peter Amenta; Su 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 294 KB 👁 2 views

Alterations of prostate biomarker expres

Alterations of prostate biomarker expression and testosterone utilization in human LNCaP prostatic carcinoma cells by garlic-derived S-allylmercaptocysteine

✍ John Thomas Pinto; Changhong Qiao; Jie Xing; Brian P. Suffoletto; Kristin B. Sch 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 472 KB 👁 2 views

Intraperitoneal P-32 after negative seco

Intraperitoneal P-32 after negative second-look laparotomy in ovarian carcinoma

✍ T. Rhett Spencer Jr.; Richard D. Marks Jr.; Jimmy O. Fenn; Joseph M. Jenrette II 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 335 KB 👁 1 views

Ikirty-one patients underwent a negative second-look laparotomy between 1976 and 1986. Fourteen patients received intraperitoneal chromic phosphate (P-32) after a negative second-look laparotomy. There has been no local recurrence (zero of 14) and no deaths attributable to recurrent disease. Local c